Ferric Derisomaltose: Uses, Side Effects, and Treatment

Ferric derisomaltose is an intravenous iron formulation used to treat iron deficiency anemia in adults who cannot tolerate or have not responded to oral iron supplements. Approved in the United States for delivery of up to 1,000 mg of iron in a single sitting, it offers a practical advantage over older intravenous options that typically require multiple smaller infusions spread over weeks.¹ The drug has accumulated a broad evidence base across kidney disease, pregnancy, inflammatory bowel disease, cancer care, and other settings, with a safety profile that compares favorably to several competing intravenous irons on key concerns like allergic reactions and phosphate drops.

What Ferric Derisomaltose Is Used For

The core indication is straightforward: iron deficiency anemia in people who need iron but can’t get enough from pills. That includes patients who experience severe gastrointestinal side effects from oral iron, those whose conditions impair iron absorption (like inflammatory bowel disease or post-surgical states), and those who need rapid correction because their anemia is clinically urgent. The ability to give 1,000 mg in one infusion is a significant logistical benefit. It eliminates the adherence problem that plagues oral iron therapy and cuts healthcare visits compared with older intravenous products that cap each dose at a few hundred milligrams.¹

In practice, the drug shows up across a wide range of clinical scenarios. Nephrologists use it for patients with chronic kidney disease. Obstetricians reach for it after postpartum hemorrhage. Oncologists give it alongside chemotherapy. Gastroenterologists prefer it for IBD-related anemia. Gynecologists use it when heavy menstrual bleeding causes severe iron depletion. The specifics of the evidence in each setting vary, but the general story is consistent: ferric derisomaltose raises hemoglobin and replenishes iron stores quickly, and its side-effect profile is manageable.

How the Infusion Works in Practice

A typical course involves a single infusion of up to 1,000 mg, administered over about 20 to 30 minutes in a clinic or infusion center. Some patients need a second dose if their total iron deficit exceeds what one session can cover, but many require only the one visit. The iron in ferric derisomaltose is bound in a carbohydrate shell (a modified dextran structure called isomaltoside), which allows the body to release the iron gradually into storage rather than flooding the bloodstream all at once. This controlled release is part of why the drug has a relatively low rate of the “labile iron” spikes that can cause oxidative stress with other formulations.²

After the infusion, blood counts typically start climbing within days. Most studies show meaningful hemoglobin increases by two to four weeks. Iron stores, measured by serum ferritin, rise rapidly and tend to stay elevated for months, which is particularly useful for patients who would otherwise need repeated treatments.

Chronic Kidney Disease

Iron deficiency anemia is almost universal in people with chronic kidney disease, especially those on dialysis or approaching it. The kidneys produce less erythropoietin, and iron losses are compounded by blood draws, dialysis circuits, and poor dietary intake. Oral iron is often ineffective in this population because of impaired gut absorption and gastrointestinal intolerance.

In a Canadian evaluation of ferric derisomaltose in patients with non-dialysis chronic kidney disease or peritoneal dialysis, a single course significantly raised hemoglobin, transferrin saturation, and ferritin, with only three adverse reactions recorded across the study group.³ The larger FERWON-NEPHRO trial, which enrolled over a thousand kidney disease patients, compared ferric derisomaltose head-to-head against iron sucrose (a widely used older IV iron). Hemoglobin response was non-inferior, meaning the two drugs performed comparably at raising blood counts. The rate of serious or severe allergic reactions with ferric derisomaltose was very low at about 0.3%, and the difference between the two drugs on that measure was not statistically significant.⁴

Pregnancy and Postpartum Anemia

Iron deficiency anemia during pregnancy and after delivery is common and can be dangerous if severe. Blood loss during childbirth, particularly in postpartum hemorrhage, can push hemoglobin to critically low levels. Oral iron simply cannot keep up in these situations.

A study of pregnant individuals with iron deficiency anemia found that a single 1,000 mg dose of ferric derisomaltose was well tolerated and significantly improved hemoglobin, iron stores, and fatigue scores.⁵ For postpartum hemorrhage specifically, a real-world comparative study showed that women who received ferric derisomaltose had significantly higher hemoglobin and ferritin levels at both two weeks and one month postpartum compared with conventional iron treatment. No cases of low phosphate were observed in either group.⁶ A Japanese phase 3 trial similarly reported rapid and sustained improvements in hemoglobin and iron stores after ferric derisomaltose for postpartum hemorrhage-associated anemia, with no new safety signals.⁷

One thing to note: when researchers compared intravenous iron (both ferric derisomaltose and ferric carboxymaltose) against oral iron at six weeks postpartum, hemoglobin levels were only slightly higher in the IV groups, and the differences were small enough that they may not matter clinically.⁸ This suggests that the biggest advantage of IV iron in the postpartum setting is speed of recovery and symptom relief in the first couple of weeks, rather than a fundamentally different hemoglobin endpoint months later.

Inflammatory Bowel Disease

People with Crohn’s disease or ulcerative colitis are particularly prone to iron deficiency, both from chronic intestinal blood loss and from impaired absorption in inflamed gut tissue. The PHOSPHARE-IBD trial is the landmark head-to-head study for this population, comparing ferric derisomaltose directly against ferric carboxymaltose (another widely used IV iron). Both drugs effectively corrected anemia, but the key finding was about phosphate levels. Only about 8% of patients receiving ferric derisomaltose developed low phosphate, compared with 51% of those receiving ferric carboxymaltose.⁹ Patient-reported fatigue scores also improved more quickly with ferric derisomaltose, and the researchers found that slower fatigue recovery was linked to bigger drops in phosphate concentration. This is an important detail because it suggests the phosphate issue is not just a lab abnormality — it may have real consequences for how patients feel.

The Phosphate Question

Low phosphate (hypophosphatemia) deserves its own discussion because it is the clearest differentiator between ferric derisomaltose and its main competitor, ferric carboxymaltose. When phosphate drops too low, people can experience muscle weakness, bone pain, fatigue, and in severe or prolonged cases, a bone-softening condition called osteomalacia. Ferric carboxymaltose drives phosphate levels down by triggering a surge in a hormone called FGF23, which tells the kidneys to dump phosphate into the urine. Ferric derisomaltose causes a much smaller rise in FGF23.

In the PHOSPHARE-IBD trial, this translated to a dramatic difference. By day 35, low phosphate occurred in about 8% of ferric derisomaltose patients versus 51% of ferric carboxymaltose patients. Extending the window out to day 70, the numbers were roughly 13% versus 59%. Urinary phosphate excretion was measurably higher in the ferric carboxymaltose group, confirming the hormonal mechanism.⁹ This difference matters most for patients who need repeated iron infusions over months or years, as chronic phosphate depletion can accumulate. For someone getting a one-time infusion for acute blood loss, the clinical significance is less clear.

Hypersensitivity and Allergic Reactions

Fear of anaphylaxis has historically been a barrier to intravenous iron therapy, partly because older iron dextran formulations carried a real (if small) risk of serious allergic reactions. Ferric derisomaltose was designed to address this concern. A meta-analysis pooling data from ten randomized controlled trials involving over 3,400 ferric derisomaltose patients found that serious or severe hypersensitivity reactions occurred in about 0.14% of cases. By comparison, ferric carboxymaltose, analyzed across seven trials and roughly 2,700 patients, had a rate of about 1.1%. The difference was statistically significant.¹⁰

True anaphylaxis with ferric derisomaltose is extremely rare. A more common but still infrequent phenomenon is the so-called “Fishbane reaction,” a brief episode of flushing, chest tightness, or back pain that can mimic an allergic reaction but is not immune-mediated and typically resolves on its own within minutes. These are uncommon with ferric derisomaltose as well.² Infusion centers still monitor patients for a short observation period after administration, which is standard for all IV iron products.

Other Side Effects and Practical Concerns

Beyond allergic reactions and phosphate levels, the most commonly reported side effects are mild: headache, nausea, and injection site discomfort. These tend to be self-limiting and rarely lead to discontinuation.

Extravasation, where the infusion leaks out of the vein into surrounding tissue, is a known complication of all intravenous iron products. When it happens, it can leave a dark stain on the skin that may persist for months or even permanently. A case report in a chronic kidney disease patient highlighted the importance of good IV access and careful monitoring during infusion to minimize this risk.¹¹ If you notice swelling, pain, or discoloration at the infusion site, alert the nursing staff immediately. Early detection and stopping the infusion can limit the damage.

There is also a transient oxidative stress effect. A pilot study in CKD patients found that markers of free (labile) iron in the blood spiked significantly within two hours of a 1,000 mg ferric derisomaltose infusion, but these levels returned to baseline within one week. A lower 200 mg dose did not produce a meaningful spike at all.¹² The clinical significance of this temporary oxidative burst is unclear, but it is something researchers are watching, especially in patients who already have high levels of oxidative stress from their underlying diseases.

Cancer-Related Anemia

Chemotherapy frequently causes or worsens anemia, and blood transfusions carry their own risks and resource costs. A retrospective Japanese study compared cancer patients who received ferric derisomaltose alongside chemotherapy to a control group. By day 21, hemoglobin had risen to an average of about 9.4 g/dL in the treatment group while it had fallen to about 7.4 g/dL in controls. The proportion of patients needing red blood cell transfusions was dramatically lower in the ferric derisomaltose group — roughly 7% versus 33%.¹³ These are compelling numbers, though the study was retrospective and single-center, so larger prospective trials would strengthen the case.

Heavy Menstrual Bleeding

Women with heavy menstrual bleeding can develop profound iron deficiency over time, sometimes reaching hemoglobin levels low enough to require hospital admission. In a study of women with severe anemia from heavy menstrual bleeding, ferric derisomaltose raised the average hemoglobin from 6.2 g/dL to 10.6 g/dL within three to four weeks, with ferritin levels jumping from about 23 μg/L to 149 μg/L.¹⁴ A separate Japanese randomized trial comparing ferric derisomaltose to saccharated ferric oxide (an older IV iron used widely in Japan) in menorrhagia patients found the hemoglobin response was non-inferior — meaning the two drugs worked comparably — but ferric derisomaltose required far fewer infusion visits to deliver the full dose.¹⁵

Use Before Surgery

Preoperative anemia is a well-established risk factor for needing blood transfusions during and after surgery, and transfusions themselves carry risks. The idea behind giving IV iron before an operation is to boost hemoglobin in advance so the patient starts surgery in better shape. The evidence for ferric derisomaltose in this setting is mixed so far.

A study of patients undergoing abdominal surgery found that ferric derisomaltose did raise hemoglobin levels before the operation, but in a post-hoc analysis that included a control group, transfusion rates were identical — an odds ratio of essentially 1.0.¹⁶ In contrast, the INITIATE trial in cardiac surgery used intravenous iron (including ferric derisomaltose-type formulations) combined with an erythropoiesis-stimulating agent and found significantly lower odds of transfusion compared with oral iron alone.¹⁷ The discrepancy may reflect the difference in surgical contexts, the addition of the erythropoiesis-stimulating agent, or simply the difficulty of demonstrating transfusion reduction in populations where many other factors determine blood loss. This is an area where more research is needed before drawing firm conclusions.

Heart Failure

Iron deficiency is common in heart failure patients, even when they are not technically anemic. The hope has been that correcting iron deficiency might improve exercise capacity, reduce hospitalizations, or even lower mortality. A health technology assessment of ferric derisomaltose for heart failure concluded that the evidence shows limited improvement in quality of life in the short term, without any effect on mortality, hospitalization rates, or exercise capacity compared to usual care.¹⁸ This is a somewhat sobering finding given the enthusiasm around IV iron for heart failure in recent years. It does not mean iron repletion is useless in these patients, but it suggests the benefits are modest and mostly subjective rather than hard clinical endpoints.

Pediatric Use

Data on ferric derisomaltose in children are still emerging, but early results look encouraging. A study of 72 pediatric patients (median age around 13 to 14 years) who received either ferric derisomaltose or low-molecular-weight iron dextran found comparable hemoglobin increases in both groups, with mild adverse events occurring in only about 6% of ferric derisomaltose recipients.¹⁹

A multicentre retrospective study in pediatric gastroenterology patients found that after a single infusion, roughly two-thirds completely corrected their anemia, with median hemoglobin rising from 92 g/L to 126 g/L at one month and continuing to climb over 12 months. About 20% of patients needed a second infusion, and among those, most also achieved correction. No significant low-phosphate events were detected, and adverse events occurred in about 6% of patients, with most being mild enough that only three out of 65 patients had their infusion discontinued.²⁰ For families dealing with a child who has chronic iron deficiency and cannot tolerate oral supplements, the option of a single infusion that resolves the problem for months is a meaningful quality-of-life improvement.

Cost Considerations

The economics of IV iron therapy get surprisingly interesting when you look beyond the sticker price of the drug itself. Ferric derisomaltose’s ability to deliver the full dose in fewer infusions means fewer clinic visits, fewer nursing hours, and fewer missed workdays for patients. And its lower rate of phosphate-related complications means less need for phosphate monitoring and treatment down the road.

A cost-utility analysis in England looking at IBD patients found that over five years, ferric derisomaltose required about 1.6 fewer infusions per patient than ferric carboxymaltose, saving roughly £500 per patient in infusion-related costs alone. When the costs of monitoring and treating low phosphate after ferric carboxymaltose were added, total savings reached about £722 per patient. Ferric derisomaltose came out as the less expensive option with better quality-of-life outcomes across healthcare system, provider, and societal perspectives.²¹ A similar analysis in China found parallel results: fewer infusions, lower overall costs, and a gain in quality-adjusted life years, driven largely by reduced phosphate-related fatigue.²²

When compared against iron sucrose (the multi-dose standard in many countries), the picture is slightly different. A Chinese model estimated that ferric derisomaltose cost somewhat more in direct drug procurement but provided enough quality-of-life benefit to be considered cost-effective from a healthcare system standpoint, and actually dominant — meaning cheaper and better — from a societal perspective once factors like lost productivity were included.²³ These economic models always involve assumptions and may not translate perfectly to every healthcare system, but the general pattern — that fewer visits and fewer complications offset a higher per-dose price — has been consistent across analyses.

How Ferric Derisomaltose Compares to Other IV Irons

If your doctor recommends IV iron, you may wonder why one formulation over another. The practical differences boil down to a few key factors. Ferric derisomaltose and ferric carboxymaltose both allow high single doses (up to 1,000 mg), which is their shared advantage over iron sucrose, which typically caps at 200 mg per session and requires multiple visits. Where ferric derisomaltose separates itself from ferric carboxymaltose is on the phosphate issue: across studies, the risk of low phosphate is consistently and substantially lower with ferric derisomaltose. The meta-analysis evidence also points to a lower rate of serious allergic reactions with ferric derisomaltose compared to ferric carboxymaltose.¹⁰

In terms of effectiveness at correcting anemia, the various IV iron products perform similarly. Head-to-head trials consistently show non-inferiority rather than superiority in hemoglobin response. The real differentiators are convenience, side-effect profile, and downstream costs. For patients who need repeated iron infusions over years — people with IBD, chronic kidney disease, or ongoing heavy menstrual bleeding — the cumulative advantages of fewer infusions and less phosphate depletion can add up meaningfully. For a one-time infusion after acute blood loss, the choice between formulations matters less.